Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TENAX THERAPEUTICS, INC.

(TENX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Tenax Therapeutics' : Levosimendan Drug Candidate Shows Positive Results in Hypertension Trial

04/09/2021 | 03:10pm EDT


© MT Newswires 2021
All news about TENAX THERAPEUTICS, INC.
06/11TENAX THERAPEUTICS, INC.  : Submission of Matters to a Vote of Security Holders ..
AQ
06/10TENAX THERAPEUTICS  : Set to Join Russell Microcap® Index
BU
05/17TENAX THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/17TENAX THERAPEUTICS  : Earnings Flash (TENX) TENAX THERAPEUTICS Posts Q1 Loss $-1..
MT
05/17TENAX THERAPEUTICS  : Reports First Quarter 2021 Results and Provides Business U..
BU
04/27Medical supplies flow into India as COVID-19 deaths near 200,000
RE
04/21TENAX THERAPEUTICS  : Indian COVID-19 patients die as ventilators run out of oxy..
RE
04/20Oxygen shares, real and imaginary, rally as India battles virus surge
RE
04/09TENAX THERAPEUTICS'  : Levosimendan Drug Candidate Shows Positive Results in Hyp..
MT
04/09MIDDAY REPORT : Wall Street Firmer Midday Amid Producer Prices Spike
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -33,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,20x
Yield 2021 -
Capitalization 48,4 M 48,4 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 1,94x
Nbr of Employees -
Free-Float 67,0%
Chart TENAX THERAPEUTICS, INC.
Duration : Period :
Tenax Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TENAX THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 4,75 $
Last Close Price 1,92 $
Spread / Highest target 160%
Spread / Average Target 147%
Spread / Lowest Target 134%
EPS Revisions
Managers and Directors
NameTitle
Anthony A. DiTonno Chief Executive Officer & Director
Michael B. Jebsen President & Chief Financial Officer
Gerald T. Proehl Chairman
Stuart Rich Director & Chief Medical Officer
Doug Randall Executive VP-Commercial & Business Operations
Sector and Competitors
1st jan.Capitalization (M$)
TENAX THERAPEUTICS, INC.3.23%48
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367